Quote:

---

But as our trial is design now , we will try to give to these very sick patients , with already compromised immune system , 700 mg of LL so we have a better chance to elevate PD-L1.

---

A cold tumor is the result of a compromised immune system which presents an M2 macrophage profile with abundant TREGs. Leronlimab activates the immune system by an M2 to M1 macrophage switch turning the tumors hot. A side effect of this is increasing PD-L1. In the absence of a PD-L1 inhibitor what is important is how well the M1 macrophages can overwhelm PD-L1.